Aurobindo Pharma Dilutes Stake in Step-Down Subsidiary A1 Biochem Labs
Aurobindo Pharma Ltd 路 Others (Uncategorized) 路 01 Oct 2026, 6:24 pm
Aurobindo Pharma Dilutes Stake in Step-Down Subsidiary A1 Biochem Labs Aurobindo Pharma鈥檚 wholly owned subsidiary, Apitoria Pharma, diluted its holding in step-down subsidiary A1 Biochem Labs from 100% to 80% on a fully diluted basis. Former promoter Dr. Rajendra Gadikota subscribed to 89,94,500 equity shares (INR 9.18 Cr) and 2,41,05,500 Compulsory Convertible Debentures (INR 24.62 Cr), securing a 20% stake for INR 33.80 Cr on 30th Sep'26. A1 Labs remains a subsidiary, with Apitoria retaining an option to reacquire the 20% stake in the future under agreed definitive terms.
Original exchange filing (PDF)
More announcements from Aurobindo Pharma Ltd
- Intimation of classification of US FDA inspection at Lannet Company LLC, a wholly owned subsidiary of Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company. 路 12 Nov 2026
- Submission of Earning Call Transcript for Q2FY27. 路 11 Nov 2026
- Unit-2 of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company received Establishment Inspection Report from US FDA with classification as "Voluntary Action Indicated". 路 11 Nov 2026
- Intimation of investors / analysts meet to be held on 17.11.2026. 路 09 Nov 2026
- Intimation of investor / analysts meet to be held on 16.09.2026. 路 09 Nov 2026
- Submission of Financial results for the Quarter and Half year ended September 30, 2026. 路 05 Nov 2026
- Reappointment of Mr. M. R. Kumar as Independent Director of the Company for second term with effect from April 1, 2027. 路 05 Nov 2026
- Transfer of ownership of Auro Pharma LLC, Russia from Auroactive Pharma Private Limited to Auropharm Overseas Limited, Wholly Owned subsidiaries of the Company. 路 05 Nov 2026
